WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Extended-release niacin/laropiprant (CORDAPTIVE™) coadministered with simvastatin had significant additive effects on reducing LDL-cholesterol (LDL-C), increasing HDL-cholesterol (HDL-C) and reducing triglyceride levels in a Phase III study with patients with primary hypercholesterolemia or mixed dyslipidemia. The results were presented today by Merck & Co., Inc. at the American Heart Association 2007 Scientific Sessions in Orlando, Fla.
